Manifesto for Wales

TIME TO DO THINGS DIFFERENTLY: A Plan for Change in Wales

AMSER I WNEUD

PETHAU’N WAHANOL:

Cynllun ar gyfer Newid yng Nghymru

Brain tumours are the leading cause of cancer death for people under 40 in Wales1. While other cancers have seen significant improvements in survival, brain tumour outcomes remain devastatingly stagnant2. Despite this, funding for research into brain tumours has received just 1% of UK cancer research spending since 20023

Tiwmorau’r ymennydd yw prif achos marwolaeth o ganser i bobl o dan 40 oed yng Nghymru1. Er bod cyfraddau goroesi o fathau eraill o ganser wedi gwella’n sylweddol, mae canlyniadau tiwmor yr ymennydd yn parhau’r un fath, sy’n peri pryder2. Er gwaethaf hyn, dim ond 1% o wariant ymchwil canser y DU sydd wedi’i dderbyn ar gyfer ymchwil i diwmorau’r ymennydd ers 20023.

Brain Tumour Research is the only national charity dedicated to finding a cure for all types of brain tumours. We work closely with Members of the Senedd and the Welsh Government to ensure that the voices of brain tumour patients are heard, and we serve as stewards of their experiences to influence policy and decision-making in Wales. We are funding our first major research project in Wales in partnership with the Medical Research Council (MRC). Led by Dr. Ben Newland at Cardiff University, the aim is to develop a revolutionary drug-delivery system to improve treatment for glioblastoma patients. Glioblastoma is the most aggressive and most common type of high-grade primary brain tumour in adults, with around 3,200 people diagnosed each year in the UK and less than 5% of patients surviving their diagnosis for five years4.

Brain Tumour Research yw’r unig elusen genedlaethol sy’n ymroddedig i ddod o hyd i iachâd ar gyfer pob math o diwmorau’r ymennydd. Rydym yn gweithio’n agos gydag Aelodau’r Senedd a Llywodraeth Cymru i sicrhau bod lleisiau cleifion tiwmor yr ymennydd yn cael eu clywed, ac rydym yn gwasanaethu fel stiwardiaid eu profiadau i ddylanwadu ar bolisi a gwneud penderfyniadau yng Nghymru. Rydym yn ariannu ein prosiect ymchwil mawr cyntaf

yng Nghymru mewn partneriaeth â’r Cyngor

Ymchwil Feddygol (MRC). Dan arweiniad Dr. Ben Newland ym Mhrifysgol Caerdydd, y nod yw datblygu system chwyldroadol ar gyfer dosbarthu cyffuriau i wella triniaeth ar gyfer cleifion glioblastoma. Glioblastoma yw’r math mwyaf ymosodol a mwyaf cyffredin o diwmor yr ymennydd gradd uchel ymysg oedolion, gyda thua 3,200 o bobl yn cael diagnosis bob blwyddyn yn y DU a llai na 5% o gleifion yn goroesi eu diagnosis am bum mlynedd4.

“As a bereaved mum, I am acutely and painfully aware of the historical lack of progress in brain tumour treatment and survival rates. There needs to be change and it absolutely must happen now.

“The barriers encountered by those affected by a brain tumour, from diagnosis and treatment through to end-of-life care, are both devastating and unjust. It is imperative that the Welsh Government hears the voices of those affected by brain tumours and makes a national commitment to changing the story for individuals and their families in Wales.

Brain cancer stole my daughter’s childhood and took away her life. Significant improvements in awareness, research funding and access to specialist support, trials and treatment will offer tangible hope to families like ours, whose precious loved ones deserve so much better.”

Cardiff mother Debra Gibbon who lost her daughter Jenna aged 15

“Fel mam sy’n galaru, rwy’n ymwybodol iawn o’r diffyg cynnydd hanesyddol mewn triniaeth tiwmor yr ymennydd a chyfraddau goroesi. Mae angen newid ac mae’n rhaid iddo ddigwydd nawr yn bendant.

“Mae’r rhwystrau y mae’r rhai sydd wedi’u heffeithio gan diwmor ar yr ymennydd yn eu hwynebu, o’r diagnosis a’r driniaeth hyd at ofal diwedd oes, yn ddinistriol ac yn anghyfiawn. Mae’n hanfodol bod Llywodraeth Cymru yn clywed lleisiau pobl y mae tiwmorau ar yr ymennydd yn effeithio arnynt ac yn gwneud ymrwymiad cenedlaethol i newid y stori i unigolion a’u teuluoedd yng Nghymru.

“Cymerodd canser yr ymennydd blentyndod fy merch oddi wrthi ac nid yw hi gyda ni mwyach oherwydd canser yr ymennydd. Bydd gwelliannau sylweddol mewn ymwybyddiaeth, cyllid ymchwil a mynediad at gefnogaeth arbenigol, treialon a thriniaeth yn cynnig gobaith pendant i deuluoedd fel ein un ni, y mae eu hanwyliaid gwerthfawr yn haeddu cymaint gwell.”

Mam o Gaerdydd, Debra Gibbon, a gollodd ei merch Jenna yn 15 oed

The Urgency for Change Y Brys am Newid

The first national cancer research strategy for Wales5 was launched in 2022. However, it is not clear how long the strategy will run for, and there has been no published update on progress against its recommendations and priorities. This lack of clarity makes it increasingly difficult to plan and sustain longterm research programmes.

The strategy also takes a broad, pan-cancer approach, with limited detail on how research into more complex and hard-to-treat cancers, such as brain tumours, will be supported. In the absence of clear priorities, actions or reporting, it is difficult to assess whether these cancers are being adequately addressed which risks slowing progress in areas with significant unmet need.

Lansiwyd strategaeth ymchwil canser genedlaethol gyntaf Cymru5 yn 2022. Fodd bynnag, nid yw’n glir am ba hyd y bydd y strategaeth yn rhedeg, ac nid oes diweddariad wedi’i gyhoeddi ar gynnydd yn erbyn ei hargymhellion a’i blaenoriaethau. Mae’r diffyg eglurder hwn yn ei gwneud hi’n gynyddol anodd cynllunio a chynnal rhaglenni ymchwil hirdymor.

Mae’r strategaeth hefyd yn mabwysiadu dull eang sy’n cwmpasu pob canser, gyda manylion cyfyngedig ynghylch sut y bydd ymchwil i ganserau mwy cymhleth ac anodd eu trin, fel tiwmorau’r ymennydd, yn cael ei chefnogi. Yn absenoldeb blaenoriaethau, camau gweithredu neu adrodd clir, mae’n anodd asesu a yw’r canserau hyn yn cael eu trin yn ddigonol sy’n peryglu arafu cynnydd mewn meysydd lle mae angen sylweddol heb ei ddiwallu.

BRAIN TUMOUR HEADLINES

There are more than 100 different types of brain tumour making them notoriously difficult to diagnose and treat7

In Wales, 674 people are diagnosed with a brain tumour each year8

Less than 18% of patients in Wales survive their brain cancer diagnosis for five years or more, compared to an average of more than 61% for all cancers2

PENAWDAU TIWMOR YR YMENNYDD

Mae dros 100 o wahanol fathau o diwmorau ar yr ymennydd sy’n eu gwneud yn anodd iawn i’w diagnosio a’u trin7

Yng Nghymru, mae 674 o bobl yn cael diagnosis o diwmor ar yr ymennydd bob blwyddyn8

Mae llai na 18% o gleifion yng Nghymru yn goroesi eu diagnosis o ganser yr ymennydd am bum mlynedd neu fwy, o’i gymharu â chyfartaledd o fwy na 61% ar gyfer pob math o ganser2

“As a brain tumour patient, my experience of healthcare in Wales has been incredibly difficult. A brain tumour diagnosis is frightening enough without facing gaps in care, limited treatment options and a lack of support. I am backing the Manifesto for Wales because people in Wales deserve better – better access to specialist care, better treatments and stronger support for patients and families from diagnosis onwards. Lives depend on it.”

Brain cancer patient Lauren Macpherson, 29, from Cardiff

“Fel claf tiwmor ar yr ymennydd, mae fy mhrofiad o ofal iechyd yng Nghymru wedi bod yn anhygoel o anodd. Mae diagnosis o diwmor ar yr ymennydd yn ddigon brawychus heb wynebu bylchau mewn gofal, opsiynau triniaeth cyfyngedig a diffyg cefnogaeth. Rwy’n cefnogi’r Maniffesto i Gymru oherwydd

bod pobl yng Nghymru yn haeddu gwell – gwell mynediad at ofal arbenigol, gwell triniaethau a chefnogaeth gryfach i gleifion a theuluoedd o’r diagnosis ymlaen.

Mae bywydau’n dibynnu arno.”

Claf canser yr ymennydd Lauren Macpherson, 29, o Gaerdydd

GENERAL CANCER HEADLINES FOR WALES

Late Diagnosis:

24% of patients are diagnosed at the most advanced grade6

Inequality:

Mortality rates are 52% higher in deprived communities1

Widening Gaps:

The survival gap between the most and least deprived is increasing6

Policy Recommendations for the Senedd: Accelerating Innovation and Treatment

The following three actions are required to transform outcomes for brain tumour patients in Wales. By addressing systemic barriers to clinical trials, research funding and access to whole genome sequencing, the Welsh Government can bridge the “devolution gap” and ensure Welsh brain tumour patients are not left behind.

PENAWDAU CANSER CYFFREDINOL AR GYFER CYMRU

Diagnosis Hwyr:

Mae 24% o gleifion yn cael diagnosis ar y radd fwyaf datblygedig6

Anghydraddoldeb:

Mae cyfraddau marwolaethau 52% yn uwch mewn cymunedau difreintiedig1

Bylchau’n Mynd yn Fwy: Mae’r bwlch goroesi rhwng y rhai mwyaf a lleiaf difreintiedig yn cynyddu6

Argymhellion Polisi i’r Senedd: Cyflymu Arloesedd a Thriniaeth

Mae angen y tri cham canlynol i drawsnewid canlyniadau i gleifion tiwmor ar yr ymennydd yng Nghymru. Drwy fynd i’r afael â rhwystrau systemig i dreialon clinigol, cyllid ymchwil a mynediad at ddilyniannu’r genom cyfan, gall Llywodraeth Cymru bontio’r “bwlch datganoli” a sicrhau nad yw cleifion tiwmor yr ymennydd yng Nghymru yn cael eu gadael ar ôl.

1Advancing Clinical Trials: Bringing Research to the Patient

Between 2019 and 2024, Wales hosted 120 industrysponsored cancer clinical trials, none of which were for brain cancer. Therefore of the 681 participants recruited to trials, zero were brain cancer patients9

Currently, research is heavily centralised in Cardiff, creating a geographic barrier that many brain tumour patients cannot overcome. In January 2026, of the 10 academic clinical trials for brain cancer currently active and recruiting in Wales only one is recruiting outside of Cardiff10

The Recommendation: Mandate and fund a national strategy to advance clinical trials for rare and less common cancers beyond the Cardiff hub (the current primary oncology research centre).

The Recommendation: There needs to be a greater effort to incentivise the pharmaceutical industry to set up brain tumour clinical trials in Wales by improving the speed of regulatory approvals, reducing trial start-up times, and supporting effective patient recruitment.

For English patients, the Westminster Government is proposing a “package of significant changes will be delivered with new clinical trial regulations due to take effect from April 2026. Under the new rules, around one in five studies are expected to move onto a fasttrack notification route, which will allow lowerrisk trials to start sooner, while maintaining high safety standards and freeing up experts to focus on complex and early-phase studies”11

We need to see the same progress, commitment and progression across Wales, and this can be achieved by creating regional mobile research units in regions such as West Wales and in the North (a university town such as Bangor for example), to eliminate travel burdens and increase trial recruitment. We hope the new Welsh Government will echo the Medicines and Healthcare products Regulatory Agency’s (MHRA) commitment to clinical trials in 2026 and beyond.

Hyrwyddo Treialon Clinigol: Dod ag Ymchwil i’r Claf

Rhwng 2019 a 2024, cynhaliodd Cymru 120 o dreialon clinigol canser a noddwyd gan y diwydiant, ac nid oedd yr un ohonynt ar gyfer canser yr ymennydd. Felly, o’r 681 o gyfranogwyr a recriwtiwyd i dreialon, nid oedd unrhyw un yn gleifion canser yr ymennydd9

Ar hyn o bryd, mae ymchwil wedi’i chanoli’n helaeth yng Nghaerdydd, gan greu rhwystr daearyddol na all llawer o gleifion tiwmor yr ymennydd ei oresgyn. Ym mis Ionawr 2026, o’r 10 treial clinigol academaidd ar gyfer canser yr ymennydd sydd ar waith ac yn recriwtio yng Nghymru ar hyn o bryd, dim ond un sy’n recriwtio y tu allan i Gaerdydd10

Yr Argymhelliad: Gorchymyn ac ariannu strategaeth genedlaethol i hyrwyddo treialon clinigol ar gyfer canserau prin a llai cyffredin y tu hwnt i ganolfan Caerdydd (y ganolfan ymchwil oncoleg sylfaenol bresennol).

Yr Argymhelliad: Mae angen gwneud mwy o ymdrech i roi cymhelliant i’r diwydiant fferyllol sefydlu treialon clinigol ar gyfer tiwmorau’r ymennydd yng Nghymru drwy wella cyflymder cymeradwyaethau rheoleiddiol, lleihau amseroedd cychwyn treialon, a chefnogi recriwtio cleifion yn effeithiol.

I gleifion yn Lloegr, mae Llywodraeth San Steffan yn cynnig “y bydd pecyn o newidiadau sylweddol yn cael eu cyflwyno gyda rheoliadau treialon clinigol newydd a fydd yn dod i rym o fis Ebrill 2026. O dan y rheolau newydd, disgwylir i tua un o bob pump astudiaeth symud ymlaen i lwybr hysbysu cyflym, a fydd yn caniatáu i dreialon risg is ddechrau’n gynt, gan gynnal safonau diogelwch uchel a rhyddhau

arbenigwyr i ganolbwyntio ar astudiaethau cymhleth a chyfnod cynnar”11

Mae angen i ni weld yr un cynnydd, ymrwymiad a datblygiad ledled Cymru, a gellir cyflawni hyn drwy greu unedau ymchwil symudol rhanbarthol mewn rhanbarthau fel Gorllewin Cymru ac yn y Gogledd (tref prifysgol fel Bangor er enghraifft), i ddileu beichiau

teithio a chynyddu recriwtio ar gyfer treialon. Gobeithiwn y bydd Llywodraeth newydd

Cymru yn adleisio ymrwymiad Asiantaeth

Rheoleiddio Meddyginiaethau a Chynhyrchion

Gofal Iechyd (MHRA) i dreialon clinigol yn 2026 a thu hwnt.

Integrating Innovative Tools: Whole Genome Sequencing (WGS)

Whole Genome Sequencing (WGS) represents a paradigm shift in oncology. By mapping a tumour’s entire genetic blueprint, WGS identifies the specific mutations driving a patient’s cancer. For brain tumour patients, this precision approach is:

Definitive Diagnoses: Moving beyond ”look-alike” pathologies to molecular certainty

Targeted Therapies: Matching patients with drugs designed for their specific genetic profile

Predictive Analytics: Forecasting how a tumour will respond to standard treatments

Clinical Trial Access: Identifying eligibility for cutting-edge global research

Currently, WGS requires fresh frozen tissue, as traditional chemical preservation for diagnostic purposes can degrade DNA. Despite its potential, Wales currently lacks routine WGS provisions for adult brain tumour patients, creating a “postcode lottery” for access to advanced care.

In 2018, the Health Secretary under the previous UK Government in Westminster announced an ambition to sequence five million genomes in the UK over the next five years, and yet, eight years later, we have not seen this ambition realised in England or Wales12

The 2018 ambition specifically highlights that the failure is not due to a lack of technology, but a failure of long-term investment and distribution. There is only one centre in Cardiff, and some brain tumour patients are sent to Liverpool for WGS. Welsh patients should not have to travel to England as brain tumour symptoms (fatigue, seizures or cognitive issues) make longdistance travel physically and mentally exhausting. Genomic sequencing is the key to “precision medicine”. Delays caused by travel or cross-border referrals can delay the start of targeted treatments.

The Recommendation: Standardise “Cold Chain” Logistics by mandating that the neurosurgical centre in Wales be equipped with the necessary equipment (liquid nitrogen storage or -80°C freezers) to facilitate the immediate preservation of tissue samples.

The Action: Include primary brain tumours in the National Genomic Test Directory for Wales to ensure clinicians can order WGS as a standard of care, rather than an exception.

The Recommendation: Implement suggested education for neurosurgical and pathology teams on the “Fresh-to-Frozen” protocol to ensure fresh frozen tissue is collected from all patients where eligible.

The Action: Develop accessible educational resources co-produced with patients (a leaflet for example) that explain how tissue donation directly impacts their personalised treatment plan and contributes to wider research.

Integreiddio Offer Arloesol: Dilyniannu’r Genom Cyfan (WGS)

Mae Dilyniannu’r Genom Cyfan (WGS) yn cynrychioli newid patrwm yn y maes oncoleg. Drwy fapio glasbrint genetig cyfan tiwmor, mae WGS yn nodi’r mwtaniadau penodol sy’n sbarduno canser claf. Ar gyfer cleifion tiwmor yr ymennydd, y dull manwl gywirdeb hwn yw:

Diagnosisau Pendant: Symud y tu hwnt i batholegau “tebyg” i sicrwydd moleciwlaidd

Therapïau Targedig: Paru cleifion â chyffuriau sydd wedi’u cynllunio ar gyfer eu proffil genetig penodol

Dadansoddeg Rhagfynegol: Rhagweld sut y bydd tiwmor yn ymateb i driniaethau safonol

Mynediad at Dreialon Clinigol: Nodi cymhwysedd ar gyfer ymchwil fyd-eang arloesol

Ar hyn o bryd, mae angen meinwe ffres wedi’i rhewi ar gyfer WGS, gan y gall cadwraeth gemegol draddodiadol at ddibenion diagnostig ddiraddio DNA.

Er gwaethaf ei photensial, ar hyn o bryd nid oes gan Gymru ddarpariaethau WGS arferol ar gyfer cleifion tiwmor yr ymennydd sy’n oedolion, gan greu “loteri cod post” ar gyfer mynediad at ofal uwch.

Yn 2018, cyhoeddodd yr Ysgrifennydd Iechyd o dan Lywodraeth flaenorol y DU yn San Steffan uchelgais i ddilyniannu pum miliwn o genomau yn y DU dros y pum mlynedd nesaf, ac eto, wyth mlynedd yn ddiweddarach, nid ydym wedi gweld yr uchelgais hon yn cael ei gwireddu yng Nghymru nac yn Lloegr12.

Mae uchelgais 2018 yn tynnu sylw’n benodol at y ffaith nad diffyg technoleg sy’n gyfrifol am y methiant, ond methiant buddsoddi a dosbarthu hirdymor. Dim ond un ganolfan sydd yng Nghaerdydd, ac mae

rhai cleifion tiwmor yr ymennydd yn cael eu hanfon i Lerpwl ar gyfer WGS. Ni ddylai cleifion o Gymru orfod teithio i Loegr gan fod symptomau tiwmor yr ymennydd (blinder, ffitiau neu broblemau gwybyddol) yn gwneud teithio pellter hir yn flinedig yn gorfforol ac yn feddyliol. Dilyniannu genomig yw’r peth allweddol i “feddygaeth fanwl”. Gall oedi a achosir gan deithio neu atgyfeiriadau trawsffiniol ohirio dechrau triniaethau wedi’u targedu.

Yr Argymhelliad: Safoni Logisteg “Cadwyn Oer” drwy orfodi bod gan y ganolfan niwrolawfeddygol yng Nghymru’r offer angenrheidiol (storfa nitrogen hylif neu rewgelloedd -80°C) i hwyluso cadw samplau meinwe ar unwaith.

Y Camau Gweithredu: Cynnwys tiwmorau ymennydd cynradd yng Nghyfeiriadur Profion Genomig Cenedlaethol Cymru i sicrhau y gall clinigwyr archebu WGS fel safon gofal, yn hytrach nag eithriad.

Yr Argymhelliad: Gweithredu’r addysg a awgrymir ar gyfer timau niwrolawfeddygol a phatholeg ar y protocol “Fres-i-Rewi” i sicrhau bod meinwe ffres wedi’i rewi yn cael ei chasglu o bob claf lle bo’n gymwys.

Y Camau Gweithredu: Datblygu adnoddau addysgol hygyrch a gynhyrchir ar y cyd â chleifion (taflen er enghraifft) sy’n egluro sut mae rhoi meinwe yn effeithio’n uniongyrchol ar eu cynllun triniaeth personol ac yn cyfrannu at ymchwil ehangach.

3

Greater focus on funding

According to Health and Care Research Wales (the funding wing for research) which was established in 2015, only one brain tumour research project has been supported – with no further projects in this area funded since 202213. This lack of funding from the Welsh Government is likely to slow progress in understanding and treating brain tumours, limit opportunities for patients to participate in clinical trials, and reduce the ability for Wales to attract industry investment and scientific talent.

The Recommendation: Increase targeted funding for brain tumour research opportunities provided by Health and Care Research Wales to address the current funding gap.

The Action: Hold Welsh Government and Health and Care Research Wales to account for the number of brain tumour research opportunities they are funding.

3

Mwy o ffocws ar gyllid

Yn ôl Ymchwil Iechyd a Gofal Cymru (yr adain ariannu ar gyfer ymchwil) a sefydlwyd yn 2015, dim ond un prosiect ymchwil tiwmor yr ymennydd sydd wedi cael ei gefnogi – heb unrhyw brosiectau pellach yn y maes hwn wedi’u hariannu ers 202213. Mae’n debygol y bydd y diffyg cyllid hwn gan Lywodraeth

Cymru yn arafu cynnydd o ran deall a thrin tiwmorau’r ymennydd, yn cyfyngu ar gyfleoedd i gleifion gymryd rhan mewn treialon clinigol, ac yn lleihau gallu

Cymru i ddenu buddsoddiad gan y diwydiant a thalent wyddonol.

Yr Argymhelliad: Cynyddu cyllid wedi’i dargedu ar gyfer cyfleoedd ymchwil tiwmor yr ymennydd a ddarperir gan Ymchwil Iechyd a Gofal Cymru i fynd i’r afael â’r bwlch cyllido presennol.

Y Camau Gweithredu: Dwyn Llywodraeth Cymru ac Ymchwil Iechyd a Gofal Cymru i gyfrif am nifer y cyfleoedd ymchwil i diwmorau’r ymennydd y maent yn eu hariannu.

Summary of Core Recommendations, Strategic Actions, and Intended Impact

1. Increase access to clinical trials, fund satellite centres and mobile units beyond Cardiff. Increase brain tumour trial recruitment from 0% to 10% over the next Senedd session

2. Embrace WGS for brain tumour patients to improve knowledge and diagnosis of this complex cancer and open clinical trial opportunities for100% of Welsh patients

3. Improve Welsh Government funding provided to brain tumour research opportunities by establishing a specific funding call by the end of 2026

Conclusion: A Call to Action

The current approach to brain tumour treatment in Wales is fragmented and underfunded. We cannot continue to treat the leading cause of cancer death in children and young people as a “rare disease” footnote.

By highlighting the lack of brain tumour specific clinical trials in Wales and the limited funding for research through Health and Care Research Wales, we hope to serve as a leading source for policy insights that Members of the Senedd cannot obtain from other stakeholders, and demonstrate how the discoveries and innovation emanating from our funded initiatives and from our Research Centres of Excellence can be translated into action for the Welsh brain tumour community. We will secure channels of communication with the new Welsh Ministerial Health team in the Senedd, and this Manifesto serves as the foundation for next steps and engagement.

Crynodeb o’r Argymhellion Craidd, Camau Gweithredu Strategol, a’r Effaith a Fwriadwyd

1. Cynyddu mynediad at dreialon clinigol, ariannu is-ganolfannau ac unedau symudol y tu hwnt i Gaerdydd. Cynyddu recriwtio treialon tiwmor yr ymennydd o 0% i 10% dros sesiwn nesaf y Senedd

2. Cofleidio WGS ar gyfer cleifion tiwmor yr ymennydd i wella gwybodaeth a diagnosis o’r canser cymhleth hwn ac agor cyfleoedd treialon clinigol i 100% o gleifion Cymru

3. Gwella cyllid Llywodraeth Cymru a ddarperir i gyfleoedd ymchwil i diwmorau’r ymennydd drwy sefydlu galwad ariannu benodol erbyn diwedd 2026

Casgliad: Galwad i Weithredu

Mae’r dull presennol o drin tiwmor yr ymennydd yng Nghymru yn rhanedig ac wedi’i dan-ariannu. Ni allwn barhau i drin prif achos marwolaeth canser ymysg plant a phobl ifanc fel troednodyn “clefyd prin”

Drwy dynnu sylw at y diffyg treialon clinigol penodol i diwmorau’r ymennydd yng Nghymru a’r cyllid cyfyngedig ar gyfer ymchwil drwy Ymchwil Iechyd a Gofal Cymru, rydym yn gobeithio gwasanaethu fel ffynhonnell flaenllaw ar gyfer mewnwelediadau polisi na all Aelodau’r Senedd eu cael gan randdeiliaid eraill, a dangos sut y gellir trosi’r darganfyddiadau a’r arloesedd sy’n deillio o’n mentrau a ariennir ac o’n Canolfannau Ymchwil Rhagoriaeth yn weithredu ar gyfer cymuned tiwmorau’r ymennydd Cymru.

Byddwn yn sicrhau sianeli cyfathrebu gyda thîm Iechyd Gweinidogol newydd Cymru yn y Senedd, ac mae’r Maniffesto hwn yn gwasanaethu fel y sylfaen ar gyfer y camau nesaf ac ymgysylltu.

“Being diagnosed with a glioblastoma turns your world upside down in an instant. I’ve had to raise more than £100,000 to access private treatment in Germany, treatment that simply isn’t available on the NHS or here in Wales. No one facing a brain tumour should have to fundraise to survive. Lives, families and futures are profoundly impacted by this disease, yet brain tumours remain desperately underfunded. The Manifesto for Wales is a vital step towards change. We urgently need better funding, fairer access to treatment, and a commitment to research so people are given real options, not impossible choices. Patients deserve hope, not postcode lotteries.”

Brain cancer patient Matt Collins, 38, from Aberdare

“Mae cael diagnosis o glioblastoma yn troi eich byd wyneb i waered mewn eiliad. Rydw i wedi gorfod codi dros £100,000 i gael mynediad at driniaeth breifat yn yr Almaen, triniaeth nad yw ar gael ar y GIG nac yma yng Nghymru. Ni ddylai neb sy’n wynebu tiwmor ar yr ymennydd orfod codi arian i oroesi. Mae bywydau, teuluoedd a’r dyfodol yn cael eu heffeithio’n fawr gan y clefyd hwn, ond mae tiwmorau’r ymennydd yn parhau i fod heb ddigon o arian. Mae’r Maniffesto i Gymru yn gam hanfodol tuag at newid. Mae angen cyllid gwell, mynediad tecach at driniaeth, ac ymrwymiad i ymchwil ar frys arnom fel bod gan bobl opsiynau go iawn, nid dewisiadau amhosibl. Mae cleifion yn haeddu gobaith, nid loteri cod post.”

Claf canser yr ymennydd Matt Collins, 38, o Aberdâr

THE TIME TO DO THINGS DIFFERENTLY IS NOW.

We urge the Senedd to commit to these changes and give brain tumour patients the fighting chance they deserve.

NAWR YW’R AMSER I WNEUD PETHAU’N WAHANOL.

Rydym yn annog y Senedd i ymrwymo i’r newidiadau hyn a rhoi’r cyfle teg y mae cleifion tiwmor yr ymennydd yn ei haeddu.

Our Centre of Excellence Partners

Our Member Charities

Our Fundraising Groups

Tel: 01908 867200 | info@braintumourresearch.org | www.braintumourresearch.org

Brain Tumour Research, Suite 37, Shenley Pavilions, Chalkdell Drive, Shenley Wood, Milton Keynes MK5 6LB Registered charity number SC046840 (Scotland) 1153487 (England & Wales). Company limited by guarantee number 08570737

References: 1. Public Health Wales (2025). Wales: Cancer mortality in Wales, 2002-2024. Accessed: 17 September 2025: Wide inequalities in cancer death rates in Wales remain - with no recent improvement - Public Health Network Cymru. 2. Public Health Wales (2021). Cancer survival in Wales, 2002–2021: Residents of Wales aged 15-99 years. https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-reporting-tool-official-statistics/cancer-survival/. Data based on those diagnosed 2017 – 2021. 3. National Cancer Research Institute (2024). Cancer research funding data, 2020/21. Accessed: 8 February 2024: https://braintumourresearch.org/blogs/research-campaigning-news/fewer-new-cancer-research-projects-funded-during-the-pandemic Sefydliad Ymchwil Canser Cenedlaethol (2024). Data cyllido ymchwil. 4. Girardi, F., Matz, M., Stiller, C., You, H., Marcos Gragera, R., Valkov, M. Y., Bulliard, J. L., De, P., Morrison, D., Wanner, M., O’Brian, D. K., Saint-Jacques, N., Coleman, M. P., Allemani, C., & CONCORD Working Group (2023). Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro-oncology, 25(3), 580–592. https://doi.org/10.1093/neuonc/noac217. 5. Health and Care Research Wales (2022). New roadmap unveiled to boost cancer research for patients across Wales. (Accessed 2026) https://healthandcareresearchwales.org/about/news/ roadmap-cancer-research-patients-wales. 6. Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., von Deimling, A., & Ellison, D. W. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology, 23(8), 1231–1251 (Publication). 7. Cancer Research UK (2025). Brain, other CNS and intracranial tumours incidence statistics. Accessed: March 2025: https://www.cancerresearchuk.org/about-cancer/brain-tumours. 8. Audit Wales (2025). Cancer Services in Wales: A review of the strategic approach to improving the timeliness of diagnosis and treatment. January 2025. Accessed: November 2025: https://www.audit.wales/publication/cancer-services-wales Archwilio Cymru (2025). Gwasanaethau Canser yng Nghymru: Adolygiad. 9. Health Care and Research Wales (2025). Tackling cancer through research: Collaborating and delivering for patients in Wales (excludes paediatric patients). https://healthandcareresearchwales.org/sites/default/files/2025-06/Tackling_cancer_through_research.pdf. 10. NIHR (2026). Be Part of Research: https://bepartofresearch.nihr.ac.uk/results/searchresults?query=&location=. 11. MHRA (2026). Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation https://www.gov.uk/government/news/patients-to-benefit-sooner-as-uk-boosts-clinical-trials-attractiveness-with-faster-assessments-and-agile-regulation. 12. Department for Health and Social Care (2018). Matt Hancock announces ambition to map 5 million genomes https://www.gov.uk/government/news/matt-hancock-announces-ambition-to-map-5-million-genomes. 13. Health and Care Research Wales (2025). Our funded projects (accessed 2026) https:// healthandcareresearchwales.org/funding/our-funded-projects.

Cyfeiriadau: 1. Iechyd Cyhoeddus Cymru (2025). Cymru: Marwolaethau canser yng Nghymru: 2002 2024.Cyrchwyd: 17 Medi 2025: Mae anghydraddoldebau eang mewn cyfraddau marwolaethau canser yng Nghymru yn parhau - heb unrhyw welliant diweddar - Rhwydwaith Iechyd Cyhoeddus Cymru. 2. Iechyd Cyhoeddus Cymru (2021). Goroesi canser yng Nghymru, 2002–2021: Preswylwyr Cymru 15-99 oed. https://icc.gig.cymru/gwasanaethau-a-thimau/uned-deallusrwydd-a-gwyliadwriaeth-canser-cymru-wcisu/offeryn-adrodd-canser-cymraeg/goroesi-canser/. Data yn seiliedig ar y rhai a gafodd ddiagnosis rhwng 2017 a 2021. 3. Sefydliad Ymchwil Canser Cenedlaethol (2024). Data cyllido ymchwil canser, 2020/21. Cyrchwyd: 8 Chwefror 2024: https://braintumourresearch.org/blogs/research-campaigning-news/fewer-new-cancer-research-projects-funded-during-the-pandemic. 4. Girardi, F., Matz, M., Stiller, C., You, H., Marcos Gragera, R., Valkov, M. Y., Bulliard, J. L., De, P., Morrison, D., Wanner, M., O’Brian, D. K., Saint-Jacques, N., Coleman, M. P., Allemani, C., a CONCORD Working Group (2023). Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3).Neuro-oncology, 25(3), 580–592.https://doi.org/10.1093/neuonc/noac217. 5. Ymchwil Iechyd a Gofal Cymru (2022). Dadorchuddio map trywydd newydd hybu ymchwil canser gleifion ledled Cymru. (Cyrchwyd 2026) https://ymchwiliechydagofalcymru. org/about/news/map-trywydd-ymchwil-canser-gleifion-cymru. 6. Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., von Deimling, A., ac Ellison, D. W. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology, 23(8), 1231–1251 (Cyhoeddiad). 7. Ymchwil Canser y DU (2025). Brain, other CNS and intracranial tumours incidence statistics. Cyrchwyd: Mawrth 2025: https://www.cancerresearchuk.org/about-cancer/brain-tumours. 8. Archwilio Cymru (2025). Gwasanaethau Canser yng Nghymru: Adolygiad o’r dull strategol o wella amseroldeb diagnosis a thriniaeth. Ionawr 2025. Cyrchwyd: Tachwedd 2025: https://www.audit.wales/cy/cyhoeddiad/gwasanaethau-canser-yng-nghymru. 9. Gofal Iechyd ac Ymchwil Cymru (2025). Mynd i’r Afael â Chanser trwy Ymchwil: Cydweithredu a chyflawni ar gyfer cleifion yng Nghymru (heb gynnwys cleifion pediatrig). https://healthandcareresearchwales.org/sites/default/files/2025-06/Tackling_cancer_through_research_cy.pdf. 10. NIHR (2026). Be Part of Research: https://bepartofresearch.nihr.ac.uk/results/search-results?query=&location=. 11. MHRA (2026). Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation https://www.gov.uk/government/news/patients-to-benefit-sooner-as-uk-boosts-clinical-trials-attractiveness-with-faster-assessments-and-agile-regulation. 12. Adran Iechyd a Gofal Cymdeithasol (2018). Matt Hancock announces ambition to map 5 million genomeshttps://www.gov.uk/government/news/matt-hancock-announces-ambition-to-map-5-million-genomes. 12. Adran Iechyd a Gofal Cymdeithasol (2018). Matt Hancock announces ambition to map 5 million genomeshttps://www. gov.uk/government/news/matt-hancock-announces-ambition-to-map-5-million-genomes. 13. Ymchwil Iechyd a Gofal Cymru (2025). Ein prosiectau a ariennir (cyrchwyd 2026) https://ymchwiliechydagofalcymru.org/cyllid/ein-prosiectau-ariennir.